Business Context and Reporting Period
This Form 8-K filing by Cocrystal Pharma, Inc. reports on events occurring on March 31, 2015. The filing primarily addresses a change in executive leadership following the resignation of the former Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance data.
Material Changes
- Executive Departure: Dr. Gary Wilcox resigned as Chief Executive Officer due to medical reasons.
- Executive Appointment: Mr. Jeffrey Meckler was appointed as Interim Chief Executive Officer, effective March 31, 2015, coinciding with the filing of the Company's Form 10-K.
- Continued Service: Dr. Wilcox remains with the Company as a director, senior advisor, and Vice Chairman of the Board of Directors. Mr. Meckler continues to serve as a director in addition to his new role.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or specific risk factors. It references a prior Form 8-K filed on March 17, 2015, for biographical information regarding Mr. Meckler and the terms of his employment agreement.
Investor Verification Points
- Verify the terms of Mr. Meckler's employment agreement referenced in the March 17, 2015 filing.
- Confirm the status of the search for a permanent Chief Executive Officer to replace the interim appointment.
- Review the concurrent Form 10-K filing for the most recent financial position of the company.